Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield WI PDL Coverage Update | Op…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - WisconsinPolicy N/A

    Medicaid-Approved Preferred Drug List (PDL) — Coverage Criteria

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Wisconsin policy alerts

    Know when Blue Cross Blue Shield - Wisconsin releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    A listing of prescription and OTC medications with coverage annotations (e.g., PA, QL, AL, DO, SP, ST) applicable to Medicaid members in Wisconsin; intended for prescribers, pharmacies, and utilization management staff.

    Policy Summary
    PayerBlue Cross Blue Shield - Wisconsin
    PolicyMedicaid-Approved Preferred Drug List (PDL) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeAdministrative — routine update (no material changes)
    Effective DateMay 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a product is annotated 'PA' before dispensing to avoid claim denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Multipledrug classes listed
    PA; QL; AL; DO; SP; STcoverage annotations
    2026-05-01effective date
    100+individual products (excerpt)

    Coverage Criteria and Product Listings

    Annotated Requirements (PA, QL, AL, DO, SP, ST)

    Coverage is indicated per drug entry by annotations. Coverage and access depend on meeting the annotation requirements below.

    Prior Authorization (PA): Drugs annotated 'PA' require prior authorization prior to coverageN/A

    Examples include many specialty biologics and selected stimulants

    Quantity Limits (QL): Drugs annotated 'QL' are subject to quantity limits as specified per product (limits are defined elsewhere in the PDL)See product-level QL rules

    QL appears across inhalers, injectables, tablets, OTC items and supplies

    Age Limits / Additional Limits (AL): Drugs annotated 'AL' have age or other access restrictions noted in the listing

    Drug/Product Coding and Identifiers

    NDC/Drug product listingsNDC
    HADLIMAHADLIMA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
    HADLIMA PUSHTOUCHHADLIMA PUSHTOUCH SUBCUTANEOUS SOLUTION AUTO- INJECTOR
    HADLIMA (prefilled)adalimumab-bwwd subcutaneous solution prefilled syringe
    ADALIMUMAB-BWWDadalimumab-bwwd subcutaneous solution auto-injector
    AMJEVITAAMJEVITA SUBCUTANEOUS SOLUTION AUTO-INJECTOR
    AMJEVITA (prefilled)AMJEVITA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
    AMJEVITA-PED 10KG-<15KGAMJEVITA-PED 10KG TO <15KG SUBCUTANEOUS SOLUTION PREFILLED
    AMJEVITA-PED 15KG-<30KGAMJEVITA-PED 15KG TO <30KG SUBCUTANEOUS SOLUTION PREFILLED
    SIMLANDI (1 PEN)SIMLANDI (1 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT
    SIMLANDI (2 PEN)SIMLANDI (2 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT
    1–10 of 11
    1/2
    Drug product listings (no procedure or billing codes present)mixed
    No codes listed
    Age Limits / Quantity Limits — annotated examples
    Annotation summaryVarious products in ADHD and stimulant classes are annotated with AL (age limit) and QL (quantity limit); some stimulant formulations also include DO (dose optimization)
    Examples (stimulants)amphetamine-dextroamphetamine and methylphenidate extended‑release entries show notes including DO; AL; QL or AL; QL depending on strength/formulation

    Provider Actions — Prior Authorization, Step Therapy, Documentation

    Prior Authorization

    Obtain prior authorization for PA‑flagged products

    Certain products listed with the note 'PA' require prior authorization before benefits are approved; providers must obtain PA per the PDL before dispensing these products.

    • PA flag indicates prior authorization is required.
    Prior Authorization

    PA required for XOLAIR formulations

    XOLAIR formulations are annotated 'PA' (and often 'SP; QL'); prior authorization must be obtained before coverage is approved for any XOLAIR presentation.

    • XOLAIR subcutaneous solution auto‑injector, prefilled syringe, and reconstituted forms are noted PA; SP; QL.
    Prior Authorization

    Background and Scope

    This document is a Medicaid-Approved Preferred Drug List that organizes medications alphabetically by therapeutic class and annotates each entry with utilization controls. The legend defines shorthand used throughout the PDL — for example, PA (prior authorization required), QL (quantity limits), SP (specialty pharmacy), AL (age limits), DO (dose/dispense designation), ST (step therapy) and OTC (over-the-counter). Those annotations are the mechanism by which coverage conditions and administrative requirements are communicated to prescribers, pharmacies, and utilization management staff.

    Abbreviations and Definitions

    PA — Prior authorization
    DefinitionPA: Prior authorization is required — approval must be obtained before certain prescriptions are filled
    Where shownPA appears adjacent to many specialty biologics and selected high‑cost or restricted products (e.g., XOLAIR, MAVYRET, sofosbuvir‑velpatasvir)
    Provider actionSubmit a prior authorization request per payer procedures for products annotated 'PA' to avoid claim denial
    QL — Quantity limits
    DefinitionQL: Quantity limits — certain medications have specified quantity limits per prescription or per month
    Where shownQL is noted across classes including inhalers, antivirals, antipsychotics, and OTC/topical products (examples: albuterol inhalers, oseltamivir, TRIDERM)

    Step Therapy and Specialty Routing

    ItemStep therapy note
    Drugs annotated 'ST' (step therapy)
    Step therapy requires that a specified medication be tried first before alternatives are authorized (ST = Step therapy is required)
    Product / ClassNote
    Anti‑IgE monoclonal antibodies (e.g., XOLAIR formulations)
    Marked 'SP' indicating specialty pharmacy handling; may imply specialty program or step requirements as noted in the formulary (PA; SP; QL present for XOLAIR)
    Example products / classesAnnotations
    High‑cost specialty classes (e.g., PCSK9 inhibitors; selected antineoplastics such as imatinib, gefitinib)
    Annotated 'PA; QL; SP' indicating prior authorization, quantity limits, and specialty management may apply before coverage
    ObservationDetails
    Step therapy presence noted
    Some products include 'SP' and 'QL' notes suggesting step therapy may exist, but explicit step sequences or required first‑line agents are not provided in this excerpt
    AgentsImplication
    Antiretrovirals and select antivirals (e.g., PREZISTA, EDURANT) and other specialty agents
    Designated 'PA' or 'SP' indicating prior authorization and/or specialty pharmacy routing may be required prior to coverage
    FindingConsequence
    No step therapy sequences specified in this excerpt
    Entries shown are formulary listings with annotations (AL; QL) but no explicit ST rules in these chunks
    ProductAnnotations
    SELARSDI (subcutaneous solution; prefilled syringe)
    Annotated 'PA; SP; QL' indicating prior authorization, specialty pharmacy handling, and quantity limits
    ItemManagement pathway
    SELARSDI and certain biologics
    Managed under specialty and prior authorization pathways before coverage (entries show 'PA; SP; QL')

    Quantity Limits and Supply Restrictions

    Multiple stimulant formulations — QL per product
    Stimulant formulationsMultiple stimulant formulations (amphetamine‑dextroamphetamine, methylphenidate ER variants) are annotated with QL; many also include DO and AL for specific strengths/forms
    ExamplesAmphetamine‑dextroamphetamine ER entries list DO; AL; QL or AL; QL depending on strength; methylphenidate ER entries show DO; AL; QL or AL; QL by strength
    ImplicationPharmacists should verify QL and age/dispense constraints before dispensing stimulants
    Adalimumab‑bwwd and biosimilars — QL noted
    Adalimumab‑class QL notesAdalimumab‑referenced products (adalimumab‑bwwd, AMJEVITA, HADLIMA) are annotated 'PA; SP; QL' across formulations
    ExamplesHadlima PushTouch and prefilled syringes, Amjevita auto‑injector/prefilled syringe examples all show PA; SP; QL notes

    Biosimilars and Reference Biologics

    Note

    Policy Revision History

    2026-05-01policy_effectiveLatest

    PDL became effective May 1, 2026 for Medicaid members (Medicaid‑Approved Preferred Drug List).

    Policy Summary
    PayerBlue Cross Blue Shield - Wisconsin
    PolicyMedicaid-Approved Preferred Drug List (PDL) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeAdministrative — routine update (no material changes)
    Effective DateMay 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a product is annotated 'PA' before dispensing to avoid claim denial.
    SourceLink
    On This Page
    Coverage Criteria and Product ListingsDrug/Product Coding and IdentifiersProvider Actions — Prior Authorization, Step Therapy, DocumentationBackground and ScopeAbbreviations and DefinitionsStep Therapy and Specialty RoutingQuantity Limits and Supply RestrictionsBiosimilars and Reference BiologicsPolicy Revision History
    Age- or population-specific restrictions as listed

    AL annotations appear for selected contraceptives, topical and other products

    Dose Optimization / Dispense Notes (DO): Entries annotated 'DO' indicate dose-optimization or dispensing designations that affect how the product is providedN/A

    DO appears adjacent to certain formulations (see listing)

    Specialty Pharmacy (SP): Drugs annotated 'SP' are managed through the specialty pharmacy channel and may require specialty handling and documentationN/A

    Examples include many biologic agents and some antiretrovirals

    Step Therapy (ST): Drugs annotated 'ST' require step therapy — a specified medication must be tried and documented before an alternate agent is authorizedN/A

    ST presence is indicated in the PDL; specific sequences are defined in the payer's step therapy rules

    Implications of annotations: Requests that do not meet the applicable annotation requirements (PA, SP, QL, AL, ST, DO) may be denied or require additional documentationN/A

    Prescribers should supply required documentation (e.g., indicate 'OTC' on prescriptions for OTC items when covered)

    Listed products with coverage flags

    Coverage listing and notes

    Listing: This section lists topical OTC products and select prescription topical agents with appended notes indicating coverage status: 'OTC' (over-the-counter), 'QL' (quantity limit), 'PA' (prior authorization), and 'AL' (additional label).

    Entries are product lines; no explicit medical necessity criteria provided in these chunks.

    This document is a formulary-style Preferred Drug List (PDL) that organizes medications by therapeutic class and indicates coverage annotations alongside each product. The extract does not contain standalone exclusion statements; instead, coverage implications are conveyed through the listing and the shorthand notes in the legend (for example, PA, QL, AL, DO, SP, ST).

    The provided legend excerpt does not state discrete clinical coverage criteria or explicit exclusions — it presents product lines with attached utilization annotations. Coverage and administrative requirements are implied by those annotations rather than by separate criteria text; for example, entries show OTC and QL next to many products and the legend defines the shorthand used.

    Within this excerpt coverage is expressed only via the formulary shorthand notes. The extract includes items annotated with PA (prior authorization), SP (specialty pharmacy), QL (quantity limits), AL (age/access limits) and DO (dose/dispense designation). No further clinical rule text or step sequences are provided in these chunks.

    No explicit exclusions are stated in the partial extract. The listing approach implies coverage is limited to items shown under the PDL headings and subject to any annotations; absence of a product from the extraction does not by itself constitute an exclusion statement in the provided text.

    This partial extract does not include additional coverage-criteria sections beyond the formulary listings and legend definitions shown. No separate coverage decision logic or clinical-necessity rules are present in these chunks.

    The supplied extract does not contain further coverage-criteria content for other classes beyond the product listings and notes in the fragments provided. Additional criteria may exist in the full PDL but are not present in this partial extract.

    Interpretation
    Where AL or QL appears next to a product, the product is subject to age-based restrictions and/or payer quantity limits per listing

    PA required for listed antineoplastics and select agents

    Selected agents in the antineoplastic and antibiotic listings (e.g., linezolid; imatinib; gefitinib) are annotated 'PA' (and often 'SP; QL'); prior authorization must be obtained for these agents.

    • Imatinib mesylate: Notes = PA; SP; QL.
    • Gefitinib: Notes = PA; SP; QL.
    • Linezolid and other agents in these sections include PA/QL annotations.
    Prior Authorization

    Obtain PA for specified LAI antipsychotics

    Long‑acting injectable antipsychotics such as INVEGA SUSTENNA, INVEGA TRINZA, ABILIFY MAINTENA and ARISTADA are annotated 'PA' and require prior authorization prior to coverage.

    • INVEGA SUSTENNA and INVEGA TRINZA are listed with Notes = PA (and AL/QL where shown).
    • ABILIFY MAINTENA / ARISTADA entries in the LAI antipsychotic section are PA‑flagged.
    Prior Authorization

    PA required for select antivirals/antiretrovirals

    Select antiretroviral/antiviral agents (for example, BIKTARVY, TROGARZO, SUNLENCA) are annotated with PA (and often SP/QL); providers must submit prior authorization requests for these products.

    • BIKTARVY: Notes = SP; QL (PA may apply per adjacent notes).
    • TROGARZO: Notes = PA; SP; QL.
    Prior Authorization

    PA required for listed antiviral/hepatitis agents

    Several antiviral and hepatitis agents (e.g., VIREAD/tenofovir DF, MAVYRET, sofosbuvir‑velpatasvir) are annotated 'PA' (often with SP and QL); prior authorization is required before coverage.

    • VIREAD (tenofovir df): Notes = PA; SP; QL.
    • MAVYRET and sofosbuvir‑velpatasvir: Notes = PA; SP; QL.
    Note

    OTC/AL annotations present — PA not always specified

    Some products in the listing are annotated OTC or AL without an explicit PA requirement in this excerpt; providers should follow the prescription and coverage labeling (e.g., indicate 'OTC' on prescriptions when applicable).

    • OTC designation means over‑the‑counter product available with a prescription; prescribers should indicate 'OTC' on the prescription.
    Prior Authorization

    PA required for select decongestant/antihistamine products

    Decongestant/antihistamine products such as CLARITIN‑D, ALLEGRA‑D and ZYRTEC‑D are annotated 'PA' (and/or AL; OTC; QL) in the listing; prior authorization is required for these PA‑flagged products.

    • CLARITIN‑D entries: Notes = PA; AL; OTC; QL.
    • ALLEGRA and ZYRTEC product lines include OTC/PA/QL annotations depending on formulation.
    Prior Authorization

    PA required for specified topical agents

    Certain topical agents are annotated 'PA' (e.g., TRIDERM external cream; some ciclopirox products); prior authorization must be obtained per the PDL for these topical formulations.

    • TRIDERM external cream: Notes = PA; QL.
    • Ciclopirox external solution/cream: Notes = PA; QL.
    Prior Authorization

    PA required for listed topical and diagnostic items

    Specific listed items are annotated 'PA' (e.g., podofilox external solution; lidocaine external patch 5%; TRUE METRIX test strips); obtain prior authorization before coverage to avoid denial.

    • Podofilox external solution: Notes = PA; QL.
    • Lidocaine external patches and certain strengths: Notes include OTC; QL and some PA annotations.
    • TRUE METRIX blood glucose test strips: Notes = PA; OTC; QL.
    Prior Authorization

    PA required for specified CGM and insulin delivery devices

    Continuous glucose monitoring (CGM) components and certain insulin delivery system kits/pods (e.g., DEXCOM G6/G7, FreeStyle Libre series, OMNIPOD kits/pods) are annotated 'PA' (and QL); prior authorization is required for these devices.

    • DEXCOM G6/G7 sensors, transmitters, receivers: Notes = PA; QL.
    • FREESTYLE LIBRE sensors/readers (various generations): Notes = PA; QL.
    • OMNIPOD DASH kits/pods: Notes = PA; QL.
    Step Therapy

    Follow step therapy when 'ST' is indicated

    Drugs annotated 'ST' on the PDL require step therapy — a specified medication must be tried first before alternatives are authorized; providers must follow step therapy requirements when submitting PA/coverage requests.

    • ST flag indicates step therapy is required prior to authorization of alternate agents.
    Note

    Specialty‑designated products (SP) — route and step implications

    Products marked 'SP' indicate specialty pharmacy designation and may have specialty or step implications; providers should route prescriptions through specialty channels and follow any specialty/step procedures required by the payer.

    • SP flag denotes specialty pharmacy handling; may require PA and QL as shown next to many specialty agents.
    Note

    Utilization controls for specialty/high‑cost classes

    High‑cost specialty classes (for example, PCSK9 inhibitors and some antineoplastics) are annotated with utilization controls (e.g., 'PA; QL; SP'); these annotations imply prior authorization, specialty handling, and potential step or quantity controls before coverage.

    • PA; QL; SP annotations together indicate multiple utilization management controls that may include step requirements elsewhere in the full PDL.
    Note

    SP/QL flags present — no step sequences shown in excerpt

    The PDL excerpt includes 'SP' and 'QL' flags for many products but does not specify explicit step therapy sequences in this excerpt; providers must consult the full PDL or PA criteria for detailed step rules.

    • Presence of SP/QL flags signals potential step or quantity controls but no step sequence is provided here.
    Note

    SP/AL annotations present — alternatives not specified here

    Listings include 'SP' and 'AL' annotations for certain products (specialty or access/age limits) without explicit multi‑step sequences in this excerpt; follow payer guidance for any required alternatives or routing.

    • AL and SP flags may indicate age/access limits or specialty routing; check full policy for required sequences or alternatives.
    Note

    No step therapy sequences specified in excerpt

    No explicit step therapy sequences are provided in these chunks of the PDL excerpt; where step therapy applies, detailed sequences and prior medications to try first must be confirmed in the full PDL or PA criteria.

    • Excerpt shows presence/absence of flags only; consult full policy for sequences.
    Note

    SELARSDI and similar specialty agents require SP and PA handling

    Some systemic or specialty products (for example, SELARSDI) are annotated 'SP' (and 'PA; QL'); these specialty‑flagged agents may be subject to specialty program routing and prior authorization requirements.

    • SELARSDI: Notes = PA; SP; QL — prior authorization and specialty pharmacy handling expected.
    Note

    Inventory item present — no summary provided

    This inventory item is present in the listing but no summary details are provided in the excerpt; follow the PDL entries and PA processes for any action required.

    Note

    No explicit step therapy sequences in these chunks

    No explicit step therapy sequences are provided in these chunks; providers should not assume the existence of a specific step algorithm from the excerpt and must check full program rules when ST or SP flags appear.

    Note

    Inventory item present — details not provided

    This inventory item is present in the listing but no summary details are provided in the excerpt; consult the full PDL for any authorization or routing requirements.

    Documentation Required

    Indicate 'OTC' on prescriptions for covered OTC items

    For covered OTC products listed on the PDL, prescribers should indicate 'OTC' on the prescription to ensure correct processing under the plan's coverage rules.

    • OTC notation on prescriptions is required for OTC products covered with a prescription.
    Documentation Required

    Provide documentation per PA/QL/SP notes when required

    Listings include utilization notes (PA, SP, QL, DO, OTC) adjacent to products; providers must supply documentation as required by prior authorization and quantity‑limit processes when submitting PA or claims.

    • Provide medical necessity, prior therapy, dosage, and any specialty routing documentation as requested in PA processes.
    Documentation Required

    Include clinical documentation for PA/QL/SP agents (e.g., imatinib, gefitinib)

    Entries for selected agents (for example, linezolid, imatinib, gefitinib) include 'PA; QL' and/or 'SP' notes; when submitting PA requests for these agents, include supporting clinical documentation consistent with PA and specialty pharmacy requirements.

    • Include diagnosis, prior treatments, dosing, and rationale for use to support PA and quantity‑limit requests.
    Documentation Required

    Respond to PDL shorthand flags with required administrative documentation

    The PDL uses shorthand flags (PA, SP, QL, AL, DO); when these annotations appear next to a product, providers must follow the payer's administrative processes (PA submission, specialty routing, quantity‑limit documentation) to secure coverage.

    • PA = Prior authorization required; SP = Specialty Pharmacy; QL = Quantity limit; AL = Age/Access limit; DO = Dispense/other dispensing note.
    Documentation Required

    Submit standard PA/QL documentation when annotations appear

    PA or QL annotations adjacent to products indicate administrative controls; providers should follow standard PA and quantity‑limit documentation procedures per the payer when requesting coverage.

    • For PA requests, include clinical justification and any required prior therapy documentation.
    • For QL requests, document clinical need for quantities outside standard limits.
    Documentation Required

    PA and QL documentation required for TRIDERM

    The PDL entry for TRIDERM external cream is annotated 'PA; QL'; providers must submit PA requests and supporting documentation for coverage of TRIDERM and be prepared to meet any quantity‑limit controls.

    • TRIDERM: Notes = PA; QL — PA and quantity‑limit documentation expected.
    Documentation Required

    Provide PA and AL/QL documentation for topical immunomodulators

    Topical immunomodulators pimecrolimus and tacrolimus are annotated 'PA; AL; QL'; prior authorization and any age/access limit documentation must be submitted to support coverage.

    • Pimecrolimus external cream: Notes = PA; AL; QL.
    • Tacrolimus external ointment: Notes = PA; AL; QL.
    Documentation Required

    PA and quantity documentation required for Omnipod products

    Omnipod kits and pods are annotated 'PA; QL'; prior authorization and documentation supporting medical necessity and requested quantities should be provided when seeking coverage.

    • OMNIPOD DASH kits/pods: Notes = PA; QL — include medical justification and quantity details in PA requests.
    Denial Risk

    Risk of denial if PA is not obtained for PA‑flagged drugs

    Prescriptions for drugs marked 'PA' require prior authorization before benefits are approved; failure to obtain PA may result in claim denial or non‑coverage.

    • Obtain PA prior to dispensing PA‑flagged medications to avoid denial.
    Denial Risk

    Noncompliance with PA/SP/QL flags may trigger denial

    Products annotated with 'PA', 'SP', or 'QL' indicate utilization restrictions; if PA/SP routing or quantity limits are not met, coverage may be denied.

    • Ensure specialty routing and quantity limits are adhered to when those flags appear to prevent denial.
    Denial Risk

    PA/SP/AL flags can trigger utilization denials

    Entries with PA, SP, or AL flags represent utilization controls that can trigger denial if required authorizations, specialty processes, or age/access limitations are not satisfied.

    • Confirm member eligibility, age limits, and obtain PA/Specialty approvals as indicated on the PDL.
    Denial Risk

    PA/SP/QL for antineoplastic and antiviral products — denial risk if unmet

    Requests for listed antineoplastic and antiviral products often have PA, SP and QL annotations; failure to secure required PA or specialty handling may result in denial of coverage.

    • Imatinib and gefitinib (antineoplastics) and MAVYRET/sofosbuvir‑velpatasvir (antivirals) include PA/SP/QL — obtain required approvals.
    Denial Risk

    Verify PA flags to avoid claim denial

    Items explicitly marked 'PA' in the listing indicate prior authorization is required; absence of PA for these items on claim submission may lead to denial.

    • Verify PA requirements for each product before dispensing or submitting claims.
    Note

    Check full PDL where PA not explicitly shown

    Some listing segments include only QL/AL/OTC notes without explicit PA triggers in the excerpt; nevertheless, providers should check full PDL guidance to confirm whether PA applies for individual formulations.

    Denial Risk

    PA/QL flags may lead to denial if conditions unmet

    Products labeled 'PA' or 'QL' may trigger denial if authorization or quantity‑limit requirements are not met; obtain PA and adhere to QL limits when requested to prevent coverage denial.

    • Authorization or quantity‑limit denials are possible for PA/QL‑flagged products.
    Denial Risk

    Combined PA/SP/QL annotations increase denial risk if unmet

    Some products (for example, SELARSDI) are annotated 'PA; SP; QL', indicating combined prior authorization and specialty pharmacy requirements; claims submitted without meeting these requirements risk denial.

    • SELARSDI entries: Notes = PA; SP; QL — follow specialty PA processes.
    Denial Risk

    PA‑marked topical/diagnostic products may be denied without PA

    Products marked 'PA' in the topical and diagnostics sections (e.g., podofilox, certain lidocaine patches, TRUE METRIX strips) may be denied if PA is not obtained; obtain PA to secure coverage.

    • Podofilox: Notes = PA; QL.
    • TRUE METRIX strips: Notes = PA; OTC; QL.
    Denial Risk

    PA required for CGM devices — denial risk without PA

    Claims for CGM devices and components (DEXCOM G6/G7, FREESTYLE LIBRE) marked 'PA' may be denied if prior authorization is not obtained; submit PA per payer requirements for device coverage.

    • DEXCOM and FREESTYLE LIBRE sensor/reader entries: Notes = PA; QL — PA required for coverage.
    Billing Rule

    PA/SP/QL apply to listed adalimumab biosimilars

    Hadlima and Amjevita (adalimumab biosimilars) are listed with Notes = PA; SP; QL; providers must follow specialty pharmacy and prior authorization processes for these biologic products.

    • Hadlima entries: Notes = PA; SP; QL.
    • AMJEVITA entries: Notes = PA; SP; QL.
    Note
    ImplicationClaims exceeding QL may require prior authorization or may be reduced/denied unless supported by documentation
    AL — Age limit / access restriction
    DefinitionAL: Age Limit Restrictions — indicates an age‑based restriction or access limitation for the product
    Where shownAL appears on multiple product entries (e.g., clonidine ER formulations, some antihistamines, contraceptives) to limit use by age group
    ActionConfirm patient age meets payer criteria when AL is present on a prescription prior to dispensing
    DO — Dose Optimization / dispensing note
    DefinitionDO: Dose Optimization Program / dispensing‑related note — indicates dispensing constraints or dose‑optimization measures
    Where shownDO appears with certain stimulant and other ER formulations (e.g., amphetamine‑dextroamphetamine ER, methylphenidate ER) and other product listings
    ImplicationWhen DO is noted, pharmacies should follow dose‑optimization procedures and payer dispensing guidance
    SP — Specialty Pharmacy designation
    DefinitionSP: Specialty Pharmacy — product is managed via specialty pharmacy processes
    Where shownSP is used for many biologics and complex therapies (e.g., XOLAIR, adalimumab‑class products, MAVYRET) indicating specialty handling
    ImplicationSpecialty products may require specialty dispensing channels and additional documentation for PA
    ST — Step therapy
    DefinitionST: Step therapy is required — a specified medication must be tried first before alternatives are authorized
    Where shownST annotations indicate step therapy across the PDL; explicit step sequences are not detailed in this excerpt
    Provider actionFollow step therapy requirements where 'ST' is noted; submit documentation of prior therapy when requesting exceptions or PA
    PA annotation example — XOLAIR
    Example usageXOLAIR (omalizumab) entries are annotated 'PA; SP; QL' indicating prior authorization and specialty pharmacy requirements
    ImplicationXOLAIR forms (auto‑injector, prefilled syringe, reconstituted) require PA as shown in the listing
    ActionSubmit PA with specialty pharmacy routing for coverage of XOLAIR formulations
    QL annotation example — multiple products
    Common observationMany products across classes are annotated 'QL' (e.g., antihistamines, antivirals, inhalers) indicating quantity limits apply
    ExamplesDiphenhydramine OTC variants, ALLEGRA, oseltamivir, and numerous inhaler products all include QL in their notes
    ImplicationCheck product‑specific QL details in the full PDL when processing claims or PA requests
    OTC — Over‑the‑counter annotation
    Definition / usageOTC: Over‑the‑counter — product available without prescription; prescribers should indicate 'OTC' on prescriptions when coverage with a prescription is intended
    Where shownOTC is noted for many antacids, topical antifungals, cough/cold products, and glucose/digestive test supplies
    ImplicationOTC designation may affect coverage and claims processing — follow payer instructions for OTC prescriptions
    DO — dispense as written / dispensing note (examples)
    Observation'DO' also appears adjacent to specific formulations to indicate dispense‑related notes (e.g., 'DO; QL' on certain strengths) — exact local meaning is dispensing‑related
    ExamplesSeveral antidepressant and stimulant entries include DO with QL (e.g., bupropion ER entries, methylphenidate ER entries)
    ImplicationPharmacies should interpret 'DO' as a dispensing instruction and consult payer guidance when processing these products
    QL — quantity limit appears throughout list
    PrevalenceQL appears repeatedly throughout the listing across many classes and product types (tablets, inhalers, injectables, OTC items)
    Operational noteWhen QL is present, quantity limits apply as specified elsewhere in the PDL; exact numeric limits are not provided in these chunks
    ActionRefer to full PDL product‑level QL entries for numeric limits when adjudicating claims or preparing PA requests
    PA — prior authorization appears throughout list
    PrevalencePA annotations are present throughout the formulary listing, attached to many specialty, topical, antiviral, and device items
    ExamplesEntries such as SELARSDI, podofilox external solution, TRUE METRIX test strips, and certain antiretrovirals include 'PA' in their notes
    Provider actionObtain prior authorization per payer process for any product annotated 'PA' to prevent claim denial
    SP — specialty drug designation
    Specialty examplesMany specialty biologics and antivirals are marked 'SP' (e.g., adalimumab‑class products, MAVYRET), indicating specialty drug handling
    Where shownSP frequently appears with PA and QL in listings for complex therapies
    ImplicationSpecialty drugs may require specialty pharmacy dispensing and additional authorization/documentation
    OTC — over‑the‑counter designation examples
    UsageOTC annotations appear for topical, digestive, and cough/cold products (e.g., magnesium oxide, Tinactin, various cough formulations)
    ImplicationOTC marking indicates non‑prescription availability; coverage may still be tracked by the PDL when prescribed
    Provider actionWhen covering an OTC item by prescription, prescriber should indicate 'OTC' on the prescription per legend guidance
    AL — access / age limit annotation present
    Annotation presence'AL' appears adjacent to numerous entries in the topical and systemic sections indicating access or age‑related limits (exact criteria not defined in excerpt)
    ExamplesTopical immunomodulators (pimecrolimus, tacrolimus) and multiple oral products show AL in notes
    ActionVerify patient age or access conditions when AL is present to ensure coverage compliance
    DO — dispense‑only / dispense note (context)
    Observation'DO' appears as a dispense‑related annotation on entries across drug classes (exact definition not included in chunks but context indicates dispensing designation)
    ExamplesAmphetamine and methylphenidate formulations often include DO in notes; some cardiovascular ER products also note DO; QL
    ImplicationTreat 'DO' entries as dispensing instructions and consult payer operational guidance when fulfilling these prescriptions
    Prior Authorization (PA) — legend definition
    Definition (legend)Prior authorization (PA): the process of obtaining approval of benefits before certain prescriptions are filled
    SourceLegend statement at start of PDL describes PA as prior authorization required before filling certain prescriptions
    Operational impactPA annotations on product listings indicate the need to submit authorization requests to the payer prior to dispensing
    Specialty Pharmacy requirement (SP) — legend
    DefinitionSpecialty Pharmacy (SP): product is managed via specialty pharmacy processes — often used for biologics and complex therapies
    ExamplesSP is used on listings for adalimumab‑class products, XOLAIR, MAVYRET and other specialty agents
    ImplicationClaims for SP‑designated products may require routing through a specialty pharmacy and additional documentation
    QL — quantity limit (legend)
    DefinitionQuantity Limit (QL): specifies that a product has payer‑imposed limits on quantity per prescription or per month
    ExamplesQL appears for antihistamines, antivirals, inhalers, topical agents, and many OTC items in the listing
    Provider actionCheck the full PDL for product‑level numeric limits when processing claims or PA requests
    AL — Age Limit / Additional Limitation (legend)
    Definition / noteAL: Age Limit or Additional Limitation — indicates age‑related or other context‑specific limitation in the listing (legend defines as 'Age Limit Restrictions')
    ExamplesAL appears with topical immunomodulators and numerous oral products in the PDL notes
    ImplicationConfirm age or other access criteria before dispensing when AL is indicated
    DO — Dispense Only / designation (context)
    DefinitionDO: Dispense Only / Dispensing designation — appears next to products as a dispense‑related note (legend lists DO: Dose Optimization Program)
    ContextDO is used with some ER formulations and other products; in listings it accompanies QL or AL for specific strengths/forms
    ActionFollow payer dispensing guidance where DO is present; clarify with payer if meaning is uncertain for a given product
    PA — prior authorization required (flag)
    PA (flag) meaningProducts annotated with 'PA' require prior authorization before benefits are approved
    Operational notePA flags are attached to many specialty biologics, antivirals, topical agents, and device items in the listing
    Provider actionSubmit PA requests per payer procedures for items with PA to avoid denial
    SP — specialty designation (flag)
    SP (flag) meaningSP indicates the product is a specialty drug and is managed through specialty pharmacy processes
    ExamplesMany biologics and complex antivirals show SP in combination with PA and QL
    ImplicationSpecialty routing and additional documentation are typically required for SP products
    QL — quantity limit (flag)
    QL (flag) meaningQL denotes that a product is subject to quantity limits — limits may be per fill or per month
    Operational noteQL appears across drug classes including OTC/topical items, requiring review of specific limits in the full PDL
    Provider actionWhen dispensing quantities exceed QL, obtain PA or provide documentation per payer rules
    AL — allowance/alternative / annotation (context)
    AL (context)AL is used as a formulary note abbreviation indicating access or alternative/age‑related limitations in product listings
    ExamplesAL appears in contraceptives and many other product listings accompanied by QL
    ImplicationCheck specific product entries for the meaning of AL and applicable age/access requirements
    DO — dispensing / other note (context)
    DO (contextual note)'DO' is used as a dispensing‑related annotation across classes; exact program details are not defined within the excerpt
    ExamplesDO appears with ER formulations and select oral agents alongside QL and AL
    ActionWhen DO appears, follow payer dispensing instructions and, if unclear, consult payer policy operations for clarification
    Formulary note abbreviations (AL, QL, OTC)
    Formulary abbreviationsCommon abbreviations shown in product notes include AL (age/access limit), QL (quantity limit), and OTC (over‑the‑counter)
    ExamplesContraceptives, acne products, and cough/cold lists display combinations of AL; QL; OTC in their entries
    ImplicationInterpret these abbreviations per the legend when adjudicating coverage or preparing PA requests
    PA — legend reference (later chunks)
    PA — legend referencePA indicates prior authorization is required; legend instructs that PA must be obtained before certain prescriptions are filled
    ExamplesPA appears in listings for antiretrovirals, antivirals, specialty biologics and device items
    Provider actionSubmit PA per payer process for any product annotated with PA
    QL — quantity limits (definition reference)
    QL — limits on quantity/days' supplyQL denotes quantity limits which may restrict amount per prescription or days' supply; QL is applied to many inhalers, antivirals, and OTC items
    ExamplesAlbuterol HFA, oseltamivir, and PAXLOVID entries include QL in their notes
    ImplicationConfirm product‑level numeric QL in full PDL when processing claims or PA requests
    OTC — over‑the‑counter (definition reference)
    OTC — definitionOTC indicates over‑the‑counter — product available without prescription; may still be listed for formulary reference and coverage tracking
    ExamplesMagnesium oxide, many cough/cold products, and topical antifungals are annotated OTC in the listing
    Provider actionIf prescribing an OTC product for coverage, indicate 'OTC' on the prescription per legend guidance
    AL annotation — topical examples
    AL annotation exampleTopical immunomodulators (pimecrolimus, tacrolimus) show 'PA; AL; QL' indicating an age/access limit in addition to PA and QL
    ImplicationWhen AL is present with PA/QL on topical agents, ensure age/access criteria and quantity limits are met in PA documentation
    ActionReview patient age and supply requested prior to PA submission for these products
    OTC annotation in topical sections
    OTC in topical sectionsMany topical products are designated OTC (e.g., Tinactin, Voltaren topical gel) and also display QL in notes
    ImplicationOTC designation for topical items may affect coverage and quantity adjudication
    Provider actionIndicate OTC on prescriptions when coverage is sought for OTC‑designated topicals
    PA annotation in topical sections
    PA in topical sectionsSpecific topical items (e.g., TRIDERM, podofilox, certain lidocaine patches) are annotated 'PA' indicating prior authorization requirement
    ExamplesTRIDERM external cream is noted 'PA; QL'; podofilox external solution is 'PA; QL'
    Provider actionSubmit PA with supporting documentation for topical products annotated 'PA' before dispensing
    QL annotation in topical sections
    QL in topical sectionsQuantity limits (QL) apply to many topical antifungals, corticosteroids and other topical agents (examples: ketoconazole, triamcinolone, halobetasol)
    ImplicationPharmacies should check QL when dispensing topical products to ensure compliance with payer limits
    ActionIf requested quantity exceeds QL, obtain PA or document medical necessity per payer rules
    SP annotation in topical / device sections
    SP in topical/device sectionsSP appears less frequently in topical entries but is common for biologics and device‑related specialty products
    ExamplesSELARSDI (PA; SP; QL) is a topical/systemic antipsoriatic listed with SP; many CGM/insulin delivery devices show PA; QL and may be SP managed elsewhere
    ImplicationSpecialty handling may be required for certain high‑cost topical/systemic agents and devices
    QL annotation in later topical chunks
    QL recurringQL recurs in many later topical and systemic product chunks indicating widespread application of quantity limits across the PDL
    ExamplesContraceptives, acne products, and cough remedies frequently include QL in their notes
    ActionReference the full PDL for numeric QL values for specific products during claim adjudication
    PA annotation in later topical chunks
    PA recurringPA annotations appear in later topical and systemic chunks for items such as TRIDERM, pimecrolimus, tacrolimus and select systemic agents
    ImplicationEnsure PA is obtained for these items to avoid denial; documentation should include medical necessity and prior therapy where applicable
    ActionFollow payer PA submission requirements when requesting coverage for PA‑annotated products
    AL example — topical immunomodulators
    AL example — topical immunomodulatorsPimecrolimus and tacrolimus external formulations are annotated 'PA; AL; QL' indicating age/access limits alongside PA and QL
    ImplicationFor these agents, verify age criteria and document supporting information in the PA request
    ActionDo not dispense without confirmed PA and age eligibility when AL is present
    PA — device section reference
    PA in device sectionCertain CGM components (Dexcom G6/G7 sensors, transmitters, receivers) are annotated 'PA; QL' indicating prior authorization is required for devices
    ImplicationClaims for these devices may be denied without PA; documentation should support medical necessity
    ActionSubmit PA per device/process requirements for CGM sensors and related items
    QL — device section reference
    QL in device sectionQL applies to many glucose monitoring and lancet supplies (numerous lancet products, ACCU‑CHEK, Freestyle Libre entries include QL/OTC notes)
    ExamplesActi‑lance, Autolet platforms, ACCU‑CHEK kits and lancets are annotated OTC; QL or OTC; QL in listings
    ActionObserve QL when dispensing supplies; consult full PDL for numeric monthly limits
    OTC — over‑the‑counter (document reference)
    OTC definition (document)OTC: Over the counter medication available with a prescription (Prescribers please indicate OTC on the prescription)
    ContextLegend instructs prescribers to mark OTC on prescriptions when coverage is requested for OTC items
    ImplicationFailure to indicate OTC on the prescription when required may affect processing or coverage
    SummaryEvidence in excerpt
    No explicit step therapy requirements detailed
    Chunks show PA/QL flags for products such as podofilox and lidocaine patches but do not specify ST sequences in this segment
    Device / ProductAccess requirement
    Dexcom G6/G7 components; FreeStyle Libre sensors/readers; selected Omnipod kits
    Annotated 'PA' (prior authorization) for specified continuous glucose monitoring sensors, receivers and select insulin delivery system kits/pods prior to coverage
    ImplicationCoverage for adalimumab biosimilars requires PA and specialty handling with quantity limits applied per PDL
    Multiple inhalers, injectables, and tablets — QL present
    Multiple product QL presenceNumerous inhalers, injectables and tablets across classes include QL annotations (e.g., albuterol inhalers, PREZISTA, oseltamivir)
    ImplicationQuantity limits are broadly applied — verify product‑level QL in the full PDL when processing claims or PA requests
    ActionFor SP/QL products, expect combined specialty and quantity management requirements
    Multiple listed products — QL noted (numeric limits not shown)
    Many listed productsMultiple listed products across therapeutic classes are noted with QL, but numeric limits are not provided in this excerpt
    ExamplesAntihistamines, contraceptives, antipsoriatics, and many OTC items show QL in notes
    ImplicationConsult the complete PDL for exact numeric QL values for each product
    Multiple products across classes — QL noted
    Cross‑class QL applicationQuantity limits appear across many drug classes (cardiovascular, antiretrovirals, antineoplastics) as shown by repeated QL notes
    ExamplesPREZISTA, REVATIO/ALYQ entries and many cardiovascular agents include QL annotations
    ActionValidate QL before dispensing; use PA or override processes where clinically justified
    Multiple listed products — QL noted in many entries
    Broad QL occurrenceQL is frequently applied to contraceptives, acne products and other commonly dispensed items indicating payer quantity management
    ExamplesLUTERA, MICROGESTIN, OPILL, ACCUTANE and many contraceptive brands show AL; QL or PA; QL annotations
    ImplicationCoverage and dispensing of these common products may be subject to quantity limits and/or age restrictions
    Various OTC and decongestant products — QL where noted
    OTC/decongestant QLVarious OTC and decongestant products are annotated with QL where noted (e.g., CLARITIN‑D, ALLEGRA‑D, loratadine‑D products)
    ExamplesCLARITIN‑D entries show PA; AL; OTC; QL indicating layered management for decongestant combos
    ImplicationOTC status does not preclude QL or PA annotations for certain decongestant/combo products
    Multiple OTC topical products — QL indicated
    OTC topical QLMultiple OTC topical antifungal and anti‑itch products (Tinactin, Lotrimin AF, Voltaren topical) include QL annotations
    ImplicationOTC topical items may still be subject to quantity limits for coverage purposes
    ActionCheck QL when dispensing OTC topical products listed in the PDL
    Multiple OTC products — QL noted
    Multiple OTC itemsMany OTC products across classes are included in the PDL with QL annotations (e.g., benzoyl peroxide topical, cough remedies, digestive aids)
    ImplicationInclusion in the PDL does not guarantee unrestricted coverage — QL and other flags may apply
    ActionRefer to full PDL for product‑specific coverage details when prescribing or dispensing OTC items
    TRUE METRIX test strips — PA; OTC; QL
    TRUE METRIX stripsTRUE METRIX blood glucose test strips are annotated 'PA; OTC; QL' in the listing (exact numeric limits not specified here)
    ImplicationCoverage for these strips requires PA despite OTC status and is subject to quantity limits
    ActionObtain PA and verify QL prior to dispensing TRUE METRIX strips to ensure coverage
    Generic lancets / lancing devices — QL noted
    Lancets / lancing devicesGeneric lancets and lancing devices are listed with QL and OTC annotations (multiple brands show 'OTC; QL')
    ExamplesActi‑lance, AGAMATRIX, AUTOLET and many lancet kits/devices are annotated OTC; QL
    ImplicationQuantity limits apply to lancets and related supplies; check product‑level QL for monthly allowance
    Omnipod kits/pods — QL; PA noted
    Omnipod kits/podsOmnipod Dash kits and pods are annotated 'PA; QL' indicating prior authorization and quantity limits apply
    ExamplesOMNIPOD DASH INTRO KIT, PDM, and PODS entries all show PA; QL in the listing
    ImplicationObtain PA and confirm quantity limits when requesting coverage for Omnipod kits/pods